Diagonal Bio AB (publ) ("Diagonal Bio" or the "Company") announces an order valued at approximately SEK 150,000 from Daniel Redén, a renowned horse trainer at StallZet. The order comes as a result of the successful completion of the pilot test which started in October 2024 and includes the purchase of LAMPlify® along with associated consumables.
On 3rd October 2024, Diagonal Bio announced its partnership with StallZet and Daniel Redén, to conduct a three-month pilot test using LAMPlify to detect respiratory viral infections in StallZet's trotters. StallZet is one of Sweden's leading horse trotting training facilities. The LAMPlify instrument was evaluated as a method to improve equine health by providing faster and accurate point-of-care analyses, enabling quick actions to enhance the well-being of StallZet's trot training facility.
As a result of the successful pilot test, Diagonal Bio has now secured an order from Daniel Redén for the LAMPlify platform, including consumables and support. The order is valued at approximately SEK 150,000. Furthermore, Daniel Redén and StallZet's network of professionals, including trainers, veterinarians, and specialists, will offer key connections to promote the broader international adoption of LAMPlify in the equestrian sector within the framework of the partnership regarding marketing announced on December 23, 2024.
"We are very satisfied with the results from the pilot study. We have learned a lot during this period and look forward to continuing our work in the field of horse welfare and diagnostics. The collaboration with Diagonal Bio's team has been very rewarding, as they have been both accommodating and professional throughout the entire period. It was impressive to see how quickly they developed a new genetic marker, EHV5, for us to use" - Daniel Redén, trainer at StallZet
"I am delighted to continue our work with Daniel Redén and StallZet. Their commitment to learn more about equine respiratory viruses and our shared focus on equine welfare make this collaboration both exciting and meaningful. It also shows that the platform, as we have believed since the start, is a vital and reliable tool in the equestrian field. We look forward to contributing with our know-how and technology to promote the health and well-being of horses." - Karin Wehlin, CEO, Diagonal Bio
This press release contains inside information that Diagonal Bio AB (publ) is required to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication on January 29, 2025, at 09:40 CET.
For more information, please contact:
Karin Wehlin, CEO
Phone: +46 (0)70 305 24 88
E-mail: kw@diagonalbio.com
Certified Adviser
Svensk Kapitalmarknadsgranskning AB
E-mail: ca@skmg.se
About Diagonal Bio
Diagonal Bio AB was founded in 2020 and is a Swedish biotechnology company with headquarters and offices in Lund. The Company develops the PANVIRAL® platform to detect and diagnose small sections of pathogen genomes, for example viruses, bacteria and fungi. The Company was founded with the goal of reducing human suffering by revolutionising global diagnostics of pathogen-borne diseases with proprietary technology. Diagonal Bio's patented technology can also be used for the less regulated market segments via LAMPlify®.
